It was demonstrated that improvement of anti-PD-L1 cancer immunotherapy could be achieved by functional reversion of pro-tumor TAM toward an anti-tumor phenotype via synthetic glycocalyx-mimicking nanoparticles [93]. This evidence concerns the gene CD274 and cancer.